The fact that ADCs do not appear to require expression of the target antigen is a pet peeve of mine for years - new evidence that’s it’s effect is non specific and basically slow release chemo

New work from our group delineating biomarkers and indications for Rapalink, originally from Kevan Shokat, now in the clinic with Revolution Medicines. This amazing Frankenstein-molecule can overcome acquired resistance to hormone tx and cdk4/6 inhibitors in ER+ breast cancers

We're excited to welcome Nadir Mahmood, Ph.D., as CEO and board member! His expertise will play a pivotal role as we seek to shift the way we understand disease biology through our integrated mapping of disease networks for precision therapeutics. businesswire.com/news/home/2023…

Excited about the future of Rezo with such a seasoned and balanced leader at the helm, onwards!

Great department and wonderful place to start your career!

Its been thrilling to see Rezo hitting its stride in mapping networks, prosecuting targets and drilling into drug discovery. Amazing things to come. We are excited to build the NextGen Sequence->Systems->Structures->Drugs platform!

A feature in Nature Biotechnology discusses the rise in team size in academic science and how it has generated an unintended side effect: junior scientists are less likely to secure research funding or obtain tenure and are more likely to leave academia. 🔒 go.nature.com/4dtPTx1

Doing good science is 90% finding a science buddy to constantly talk to about the project.